Thienopyrimidinediones and their use in the modulation of autoimmune disease
CA 2453274 A1 · Owner: Ingall, Anthony Howard · Inventors: Ingall, Anthony Howard; Reynolds, Rachel Heulwen; Cooper, Martin Edward
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates to a compound of formula (1); wherein: R1 and R2 each independently represent a C1-6 alkyl, C3-6 alkenyl C3-6 cycloalkyl C1-3 alkyl , or C3-6 cycloalkyl; each of which may be optionally substituted by 1 to 3 halogen atoms; R3 is isoxyzolidin-2-ylcarbonyl or tetrahydroisoxazin-2ylcarbonyl wherein each ring is optionally substituted by one hydroxy group; Q is CO- or C(R4)(R5)-(wherein R4 is a hydrogen atom or C1-4 alkyl and R5 is a hydrogen atom or hydroxy group); Ar is a 5- to 10-membered aromatic ring system wherein up to 4 ring atoms may be heteroatoms independently selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted by one …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 24, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended July 24, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 24, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.